Drugs / N-acetyl-aspartyl-glutamate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06800274 | Apr 2023 → Mar 2024 | atopic conjunctivitis, dry eye syndrome | Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetyl-aspartyl-glutamate | “This randomized, single-blind study aims to compare the efficacy and safety of N-acetyl-aspartyl-glutamate (NAAGA) and azelastine hydrochloride eye drops in patients with...” NCT06800274 ↗ |
| Known as | NAAGA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06800274 ↗ |
| Action | Inhibit | “reducing histamine release and mitigating inflammatory cascades such as leukotriene production and complement activation.” NCT06800274 ↗ |
| Modality | Peptide | “NAAGA is a neuropeptide with dual activity as a mast cell stabilizer and anti-inflammatory agent” NCT06800274 ↗ |
| Route | Other | “80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks.” NCT06800274 ↗ |